Benzinga | Nov 9, 2020 04:03PM EST

Cara Therapeutics Q3 EPS $(0.35) Beats $(0.60) Estimate, Sales $9.27M Beat $4.77M Estimate

Cara Therapeutics (NASDAQ:CARA) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.60) by 41.67 percent. This is a 52.7 percent increase over losses of $(0.74) per share from the same period last year. The company reported quarterly sales of $9.27 million which beat the analyst consensus estimate of $4.77 million by 94.26 percent. This is a 60.17 percent increase over sales of $5.79 million the same period last year.